Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Is anyone else investing in Juno before ASH?
Well what'd they say on the call?
Also is their a recording of the call?
My views and other investment
I'll reinvest in Oxis once they are >$1 per share. I was disappointed to see they pushed back the TriKE clinical trials until Q1 of '18 when they had originally planned on starting in the fall. However I understand they're not up-listing until the end of the year and until they receive the IPO capital they cannot afford to begin trials.
Q1 (So long as there are no more delays) looks like it's gonna be huge for this company. Up-list, data from OXS-1550 Phase II and TriKE clinical trials beginning.
Q1 '19 PainBrake AND GTP-004 will be on the market! Even if it's just PainBrake, that's tens of millions of dollars of cash flow coming in. This will be used to fund further TriKE trials. However hopefully by this point the company will be acquired. Personally I think the company will be acquired about 1 year after they up-list.
Side note, I'm currently invested in Cidara Theraputics with data from CD 101 being published in December. I think this company for will do well. Will probably sell a good portion after data is released and reinvest in Oxis assuming manageable dilution (currently 50 million outstanding, won't reinvest if there are >100 million outstanding after NASDAQ IPO) and no more delays for the TriKE trials.
This is from the latest article I posted.
Also, as a requirement of Closing, GT Biopharma completed a financing of over 4.5 million and retired 100% of the company's debt.
In your article, it says the company retired $14 million worth of debt, however maybe I'm wrong but I didn't see it say retired all debt on your link. Maybe it did and I just missed it.
Welp, I'm sorry I was wrong
I am still excited about the new CMO mainly because of his experience with 505 (b)(2) pathway. This will be useful in getting two of GTP's CNS drugs (not PainBrake) on the market faster and cheaper. Resulting in less dilution.
The company current has 50 million shares outstanding, with no debt and a little over $4 million in the bank. In my opinion, the company is in good shape and I'm confident the new CEO and also CMO will do well for shareholders. And lastly to reiterate, the company will be acquired next year, most likely in the winter.
The reason I believe it will drop is that once all debt is converted to shares, they'll have 16.5 million shares outstanding. Not my opinion, this is on the last slide of their summer presentation. There current market cap is about $12 million. With 16.5 million outstanding that'd be under a dollar a share. (There's no way the stock will maintain the same share price after going from 1 million outstanding to 16.5 million.) Even if we can't agree on the stock going under a $1. We can agree that after all debt is converted and they have 16.5 outstanding, they won't be able to maintain this $12 price and will severely decrease due to dilution. In the long run it'll be over $12 a share, but why buy at $12 when by September, it'll be trading at a couple dollars a share.
IMHO do not buy at these prices
I don't currently have any shares, because I am waiting for them to go down. Which given they will have an additional 15.5million shares outstanding by the end of September, I don't think I'll have to wait long. There market cap is around $9 million with about 1 million outstanding, with 16.5 million shares outstanding by the end of the month, you can understand why I'm not purchasing shares at these prices.
With new management and no debt, after all debt is converted to shares, I believe this will be a good longterm play. However, in the short-term this company will not do well because of dilution.
After converting all debt there will be 16.5 million shares outstanding. And this doesn't include the shares they'll need to IPO on the nasdaq in order to fund ongoing trials. I personally wouldn't be a buyer now, as they will be a slew of 8Ks over the coming weeks which will hammer the price of the stock. However, once all 16.5 million shares are outstanding and the stock goes below a $1, I'll buy back my position.
By the end of September I believe all debt will be converted. After all debt is converted there will be 16.5 million shares outstanding.
In terms of how much of a return, you've asked that numerous times. And the truth is I don't know!!
That depends on a few things:
first: how many shares will IPO when they up list to the nasdaq. After converting all debt they will have 16.5 million outstanding, however; how many additional shares will they sell? 33.5 million is what I hope, but it could be more. Let's say they IPO 83.5 instead, resulting in 100 million outstanding, in that case the highest the stock could go to is $100 a share. At 50 million outstanding, it could reach $200 a share, and at 150 outstanding, it could reach $66.67 a share. We won't know how many shares they'll have outstanding until they finish converting the debt and also IPO shares on the nasdaq that'll fund the trials. The good news is, after they IPO shares on the nasdaq, I don't think they'll have to sell additional shares after, because the funding from the IPO should provide them with enough money for the next 1-1.5 years. And in the fall/winter of next year, PainBrake will have completed the NDA and be on the market, generating revenue for Oxis that they can use to fund continuing trials instead of selling additional shares. Dr.Kathleen talked about this on the conference call as I'm sure you know.
Additional note: I just like you have sold my position, and am looking forward to when all debt is converted so I can come back in and purchase shares. For those of you currently holding, this stock will be under $1 by the end of next week so you really should sell and then come back in. At the end of September this will pop once the CMO is revealed so make sure to get back in before that.
The stock will be doing very well by November/December. At this point, the CMO whom previously was the CMO of Pfizer will be announced, PainBrake will be less than 12 months away from approval!! , all debt will have been converted leaving Oxis with a clean balance sheet, and Oxis will be trading on the NASDAQ. Also by this time two TriKEs will have entered the clinic with updates on how the liquid tumor 161533 compound being released. And OXS-1550 Phase II data will be available in just two/three months.
MrBond007, If by December, Oxis out-licenses the TriKE platform (which they stalked about in the conference call) and they sell PainBrake (hopefully by Christmas). Then as you say Oxis to the moon, baby!!!!!! the stock will be doing amazing. How could it not, a diabetic neuropathic drug that causes complete pain relief and is a year away from approval, a CMO who was previously the CMO of Pfizer! One of the largest pharmaceuticals companies in the world. The highly valued TriKE for liquid tumors will have entered the clinic. With results being publicly announced, AND AGAIN they can out-license the TriKE platform which has the potential to bring in millions! And the new CEO in the conference call said she has interest in acquiring more close to NDA approval CNS drugs!!!!
OXIS TO THE MOON BABY!!!!!!!!!!!
Why I think the company will uplist this year.
Reason 1:
From August 21st, press release
Under FINRA guidelines, the shares will trade under the symbol OXISD for 20 days before shifting to GTBP. The company has exceeded the funding requirement for the acquisition to close. It expects to convert all debt to equity as part of the acquisition transaction, leaving the company debt-free and able to file an application for acceptance to the Nasdaq Exchange by the end of the year.
Reason 2:
New management. Unlike with the previous split, new management is taking over, new CEO is Kathleen Smith, who co-founded Chase Pharmaceuticals which recently was sold to Allergan. Also the new CMO was previously the CMO of Pfizer. Competent, successful management whom have no interest in running a penny-stock.
Reason 3:
NEWS NEWS NEWS
The companies most promising candidate TriKE Cd16/IL15/CD33 is entering the clinic October 1st. One round is of treatment is only tree weeks long. After the first round, results should be available beginning of November. They will be measuring for CR and ORR. Next, OXS-1550 will release Phase II news in or before March of '18. Now for CNS, by Fall/Winter of '18, Pain Brake will have filed and completed NDA. Along with that, GTP-004 AND GTP-011 will be less than two years from NDA approval.
Reason 4:
Somebody posted on here that a company can't be listed on the nasdaq pre-revenue. That is incorrect, if that were the case then any small biotech company would not be qualified to be on the nasdaq. E.G Iovance biotherapeutics look at their 10K
Reason 5:
A lot of people on here are worried about cost for funding the CNS and Oncology trials. The reason I am not too concerned with the cost is because, the CNS pipeline will cost less than USD$20 million to fund and approve all three drugs. As for the oncology trials, Pain Brake will be approved and be generating revenue by the end of next year, they can use this revenue to fund the trials which is what they hinted at in the conference call, or they can sell Pain Brake and use that to fund the trials. Or they can out-license the TriKE platform to big pharma, which is another thing they discussed at in the conference call. That is what is so great about the TriKE platform, it can be used for liquid and solid tumors alike. And since Oxis doesn't have the funds necessary to run trials for Leukemia, Ovarian, Head and Neck, and Colorectal, using the TriKE platform all at the same time. They can out-license the platform and receive an up-front fee and along with certain milestone fees. And they will use this licensing revenue to fund their own trials.
Final Point: TriKe CD16/IL15/CD33 is without a doubt the most promising asset this company has. IL15 causes NK cell proliferation resulting in 350 fold increase of NK cells, with CD16/CD33 creating specificity. This is why this compound was awarded the REACH award, and why Dr. Soon-Shiong, acquired the company that is partnering with Oxis.
After converting all debt to shares, there will be 16.5 million outstanding which should bring the stock down to $1 or less. However after doing this, they will have rid themselves of all convertible debt. At this point they will up list and do an IPO, which should increase the outstanding shares to 50 million. This IPO should provide them with enough funding for at least the next 1 to 1.5 years. And by the time they need additional funding, PainBrake will be approved and they will be able to use the profits from that to fund the oncology portfolio, like they said they would in the conference call.
I'm personally hoping this stock goes under $1 in the short run.
I'm surprised biotechstocks.com didn't post a link on their website that includes the conference call, hopefully they will in the near future as some parts of the call were difficult to understand.
Here's what I'm doing.
I think this stock should be able to get up to $0.11 to $0.13 a share. At this point I will sell my shares, then I'm to wait for this stock to drop back to the $0.02 to $0.05 range which it will towards the end of August/ beginning of September once the pump ends. At this point I'm going to load up again and hold on to these new shares until the company is acquired.
On a side note, I thought you were wrong in one of your previous post about Oxis acquiring more drugs, however, the new CEO said in the conference call that they would like to acquire additional de-risked closed to NDA approval CNS drugs. Hopefully this is the case as this would really add value to Oxis.
Does anyone have a transcript from the conference call?
The CMO's name will not be released until the merger is complete.
From the press release "Also joining the company's executive management team as part of the merger will be a Chief Medical Officer (name to be disclosed upon closing), who was formerly Vice President and Chief Medical Officer and Medical Director, Oncology Clinical R&D of Pfizer, Inc. (PFE)."
Unfortunately, Oxis 1:300 reverse split has been confirmed in their recent 10Q
"Stock Split
In July 2017, the Company approved a one for three hundred reverse stock split. The Company has reported the effect of the split
retroactively for all periods presented." From page 14, 10Q
And again, the value in this company stems from two things: the TriKE platform for solid and liquid tumors and PainBrake. The merger and up list to the nasdaq will be completed by the end of September, with the TriKE for liquid tumors beginning October 1st. "This is why they want to up list by then"
Anticipated Start Date ICMJE October 1, 2017
source https://clinicaltrials.gov/ct2/show/record/NCT03214666
How much will Oxis have to raise after up listing?
The answer is quite a lot, according to their most recent 10Q they have $129 million in debt. So they will need to raise about $300 million, $129 to eliminate their debt with the remainder going towards funding clinical trials for the CNS and Oncology therapies, and general overhead cost for the next one-two years. Until they are most likely acquired.
How many hares outstanding will Oxis have after the 1:300 reverse split?
Well originally they will have 16.5 million, but then they will need to sell additional shares to obtain the $300 million that they will need. At $10 a share post reverse-split that'll mean an additional 30 million shares. However, if Oxis can get their stock to $0.10 a share, after the split they will be trading at $30 a share, which would mean they'd only have to sell 10 million shares. Which would mean only 26.5 million shares are outstanding, which isn't bad. This is why I believe they are pumping the stock on biotechstocks.com
I know it sounds obviously but the higher Oxis can get and maintain their share price, the less shares they will have to sell after the up list to fund future trials. If Oxis can get to and maintain a stock price of $0.10 per share prior to the split, which I believe they will be able to after the conference call on Wednesday evening. I think they will be okay.
I maintain my view that Mace Rothenberg will be the CMO of Oxis post merger. Also I'm excited to see what Oxis's new website will look like once new management takes over, I think along with the new site they will release a new presentation slideshow for the fall, (now that they can disclose whom the CMO is) and also discuss the funding they were able to receive through their IPO, how many shares they have outstanding, and how long these funds will last them.
Lastly, I think the stock will pop, on Thursday because of information released in the conference call Wednesday, should this happen I plan on selling my position, and then repurchasing towards the end of August when it comes back down.
1. The price jump is because this company is being pumped on biotechstocks.com from August 1st to September 1st. In exchange for $150K
2. New management (New CEO and CMO) will take control of the company on September 26th of this year. Either on or before this date, Oxis will do a reverse split, most likely prior. This is why they're pumping the stock, if they do a 1:300 reverse split at $0.02 they'll only be able to sell shares at $6 a share to fund current and future trials, meaning they have to sell a lot of shares. However, if they can get this up to $0.10 before the split, after a 1:300 reverse split the stock will be $30 a share, and they won't have to sell nearly as many shares to fund clinical trials.
3. Yes it is guaranteed, that they are up listing, because of new management. Previously when management, did a reverse split, they had no drugs in the clinic and the same poor management. The new CEO Kathleen Clarence-Smith, just sold her company Chase Pharmaceuticals for $125 million and could go up to a $1 billion should it meet certain milestones. Prior to that, in 2008 she sold a biotech company for $100 million. So she has a proven track record of success in the field, and she knows if she wants to receive the necessary funding for the clinical trials and also to sell this company at a 9 or 10 figure price, that they have to up list to a respectable exchange. As for the new CMO of the company, he was previously the CMO of Pfizer, and I'm going to assume the CMO of Pfizer has no interest in working with a penny stock company.
Finally
They have to do a reverse split, because after all convertible debt converts to shares, Oxis will have 5 billion shares outstanding, and since the NASDAQ wants companies on their exchange to trade at a minimum of $2-4 per share, it is impossible for Oxis to trade at either of those prices without a reverse split. At $2, that'd mean a $10 billion dollar market cap, Kite Pharma has about a $7 billion dollar market cap, and they're about to have an approved drug (axicabtagene ciloleucel) by the end of November. Oxis's most promising drug(s) won't be entering Phase I/II until October of this year.
In response to you and the other user who asked. Oxis currently has 5 billion shares outstanding once all debt is converted into shares. If they do a 1 for 100 split they will have 50 million shares outstanding instead of 5 billion however now you will have a 100th of the shares you now current have. For example say they do a 1:100 reverse split, and you have 100,000 shares, after the split you will now have 1,000 shares instead of 100,000. And instead of the stock being what it is now $0.04 per share, the new price will be 100X higher at $4 per share, however keep in mind that now your cost per share is also up 100X. You don't make or lose money when a company does a split or reverse split. You lose money when a company does a reverse split and then the company issued millions of new shares to new investors, which dilutes your ownership in the company.
Example, if a company has 100 shares outstanding and you own 10 shares, you own 10% of that business. If that company did a 1:10 reverse split you would now only have one share except now there's only 10 shares outstanding mean you still own 10% of the company.
The problem comes when that company does that 1:10 reverse split and then sells an additional 90 shares to investors to fund the business, in this situation you now own 1 share in a business with 100 outstanding shares(90 new shares+ the 10 original shares), meaning now you only own 1% of the business when previously you owned 10% of the business.
Just some extra comments
Oxis will at the very least be doing a 1:100 reverse split or even a 1:300 reverse split which will reduce the amount of outstanding shares from 5 billion to either 50 million or 16.5 depending on if they do 1:100 or 1:300. This will eliminate all convertible debt and Oxis will trade at over $4 a share allowing Oxis to up list to the nasdaq. After they up list, Oxis will have to sell additional shares in the company to fund the oncology and CNS pipeline. How many shares they will have to sell, really depends on the price per share of Oxis after they do the reverse split and up list.
And finally for MrBond007, there will be no 100X or 150X return on investment. In the very best case scenario there could be 10X return on investment. In order for there to be a 100X on investment, assuming you bought your shares at $0.05 per share (US currency not the British pound) the company would have to trade at $5 a share, with 5 billion shares outstanding that would mean the company is worth 25 billion. This company is worth nowhere near 25 billion dollars, not even in the ballpark. And if the company did a 1:100 reverse split today, the company would trade $4 a share with 50 million shares outstanding given it a market cap of $200 million. If they do a 1:100 reverse split they will have 50 million shares outstanding and then they will sell an additional 50 million shares on top of that to fund the clinical trials. Which would mean they'd have 100 million shares outstanding and at $4 a share that'd be a $400 million market cap, Best case scenario this company does a 1:100 reverse split, sells 50 million shares to fund the clinical trails leaving a total of 100 million shares outstanding, and gets acquired by Pfizer for $100 a share with a $10 billion dollar market cap, however the only way they'll get that much for the company is if TriKE 16IL1533 is FDA Approved and the CNS drug PainBrake is approved. Which certainly could happen, however it is no guarantee especially as the TriKE molecule has yet to enter the clinic. (It will enter the clinic October 1st of this year) Look for news on this drug and for PainBrake at Thanksgiving and Christmas time. And results for OXS-1550 in February '18.
The only thing valuable in this company is the TriKE platform and PainBrake, and the new CMO knows this, which is why a CMO from such a successful pharmaceutical company (Pfizer) is joining this company. I personally am not too concerned with how OXS-1550 does nor OXS-4235 for multiple myeloma or the triple negative breast cancer molecule. This is why in the press release, he first stated the pre-clinical data looks strong for this target therapy. Rather than first stating the clinic data for OXS-1550, because TriKE is where the true value in this company is, not in the phase II Oxis-1550 (In pre-clinical testing, TriKE 16IL1533 was superior to Rituxan in killing cancer cells). Should this TriKe molecule do well in the clinic as we will find out in November/December, the sky is the limit for what this company will be worth, should the TriKE perform poorly or not as well as intended, then this company and its stock is going to take a severe downturn and could even go bankrupt.
Kite Pharma 56.5 million shares outstanding
Juno 106 million shares outstanding
If either of these companies had 5 billion shares outstanding like Oxis, Kite would be trading at about $1.25 a share and Juno at about $0.65 a share.
Again in terms of the what is the true value of Oxis, we won't know until November/December when data from TriKE 16IL1533 is publicly released. By the end of December, if TriKE 16IL1533 does well in the clinic, and PainBrake finishes at least one of its Phase I studies, the company should have a market cap comparable to that of Juno. However keep in mind, there will at the very least be a 1:100 and more likely be 1:300 reverse split so that's something to keep in mind when figuring out your new cost per share.
I'm hoping they instead do a 1:100 instead of a 1:300. A 1:100 would leave only 50 million shares outstanding and all convertible notes would be gone, which is perfect for up listing. A 1:300 would leave just 16.5 outstanding, however my concern is they'd issued another 16.5 at up list/IPO which would heavily dilute us current holders.
Look at their Summer Presentation on their website, after converting all of their convertible debt to shares they will have 5 billion shares outstanding. So $20 a share would mean the company is sold for 100 billion dollars which is very silly. The company would be very lucky to sell for $1 or $2 a share. Again I don't think you understand that they have 5 billion shares outstanding.
You are correct, the company is being pumped by biotechstocks.com for $150K for the month of August. However, the one thing I will say about this company is that, they are brining in new management with an actual track record and they now actually have a pipeline. (New CEO has previously sold two companies, one for 100 million the other for 125 going up to potentially a billion should it hit certain milestones. And the new CMO was previously the CMO for Pfizer.)
So in terms of your concerns about management again I think you should be relieved to know new management is coming in.
In regards to the pipeline, the reason why this company has so much potential is because of the TriKE 16IL1533 and TetraKE 1615EpCAM133 for liquid and solid tumors. And they also have PainBrake for Diabetic Neuropathy, which will be on the market by the end of next year.
Prior to their partnership with University of Minnesota, you're right Oxis had no drugs in the clinic and again like you said nothing of actual value. However now they have assets more specifically PainBake and TriKE 16IL33.
I am excited for the future of Oxis and more specifically how TriKe 16IL1533 does in the clinic starting in October. Considering how powerful Interleukin 15 (IL15) is in causing NK Cell Proliferation without causing Cytokine Release Syndrome (something CAR-T has been shown to cause) and because its not an autologous cell therapy (e.g. CAR-T) it makes sense why the NIH has called IL 15 a potential cure for cancer. And why the TriKE therapy 16IL1533 was given the REACH award/grant from the NIH. Should the therapy do as well as expected in the clinic, it has the ability to replace Rituxan as the standard form of care for NHL.
I stand by my view, Oxis will be acquired before the end of next year most likely by Pfizer.
Yes, it is happening at the end of September when new management comes in.
Some of you guys are posting irrelevant things when it comes to the reverse split, the reverse split is happening regardless of how well OXS-1550 or the TriKe or TetraKE due in the clinic. Simply because Oxis still has a lot of convertible debt outstanding. It says this at the end of their summer presentation, after accounting for all convertible debt they will have 5 billion shares outstanding. And all of this will need to be converted to shares prior to their up listing or else the Nasdaq won't let them up list. So while the stock is doing well now, I expect it to go back down to $0.02 or less a share once all debt has been converted. However once all debt has been converted, they do the reverse split and up list. The company will be in really good shape. Especially with the incoming management team and the promising new clinic trials happening in October and November.
Prior to the 300:1 split Oxis will have 5 billion shares outstanding including convertible debt, this reverse split will eliminate all of their convertible debt, at a conversion rate of $0.007 per share resulting in 5 billion shares outstanding. After the 300:1 reverse split they will have 16.5 million shares outstanding. My prediction is they will IPO an additional 33.5 million to raise the necessary funds needed for TriKe CD16/IL-15/CD33 and the TetraKe for solid tumors. 33.5 million at $6 a share will give them 201 million. 18 million will be needed for the CNS pipeline, with the remainder being used for the TriKe TetraKe and OXS-1550 BiKe.
After this reverse split and IPO, they will trade on the NASDAQ, because they will have rid themselves of the convertible debt, they will have have a new CEO with an actual track record, and again their new CMO was previously the CMO of Pfizer. Am I the only one who finds that last part impressive.
And if that's not enough, look at the CNS pipeline, more specifically Pain Brake, Pain Brake is of significant value to GT BioPharma INC (previously known as OXIS)
This time I disagree, because of the new CEO. However, last time when they did the reverse split 1. they didn't replace the CEO with someone with an actual good track record in biotech, and 2. The only drugs they had in the pipeline were for triple negative breast cancer and multiple myeloma. And both were nowhere near (and to this day are nowhere near) ready for the clinic.
With
OXS-1550 in Phase II
TriKE 16IL1533 entering the clinic in October (Partnership with Altor Bioscience)
PainBrake 15-18 months away from NDA approval
and a new CEO, Dr. Clarence-Smith who has sold two companies, one of which being Chase pharmaceuticals for 125 million upfront and potentially up to an additional 875 million.
You should be fine, like others have said on the board, your new cost per share will be about $8.04 per share. However after this reverse spit they will uplist to the nasdaq. The reason I know for sure that they are uplisting is because they will finally have a new CEO. Kathleen Clarence-Smith, MD, PhD is the new CEO, and all the companies she has run prior to acquisition have been on the nasdaq. Also keep in mind that the new CMO (my guess Mace Rothenberg) used to be the CMO of Pfizer, whom I can guarantee has no interest in running a penny-stock company.
When you get a chance check out the summer presentations on the Oxis website.
OXS-3550 TriKE
OXS-1615 TetraKE for Carcinoma
PainBrake for Chronic Neuropathic Pain
These are the three drugs where the value in the company is.
OXS-3550 TriKE has been proven to superior to OXS-1550 in in vivo studies, so I don't expect OXS-1550 to pass Phase II trials, however OXS-3550 TriKE most likely will. As it has been proven to be more effective than Rituxan in killing cancer cells.
As for PainBrake, I believe that that will be licensed out to a larger pharmaceutical company for 100 million with another potential 500 million should the drug be approved.
Look at the last slide of their new presentation on their website. This reverse split of 1 for 300 is going to be terrible for current investors. I think the people who invest post split once they uplist and the new CEO takes over will do great, however I think current investors will be hurt by this split.
I didn't know that the company Oxis is acquiring has over 4 BILLION shares outstanding.
1615EpCAM133
TetraKE for solid tumors, which will enter the clinic after the TriKE molecule CD16/IL-15/CD33.
Again like the TriKE molecule for liquid tumors (targeting mainly AML). TetraKE looks to be a promising molecule for solid tumors (mainly for prostate, breast, and potentially colon cancer) this is because of the modified IL-15 crosslinker, which allows for NK cell proliferation.
The most promising piece of information about TriKEs and TetraKEs is that it targets carcinoma cells rather than any specific type of cancer cells. Meaning it has the TriKE platform can be used on a myriad of cancers subtypes.
For the previous post in regards to who will be the next CMO again, my guess is still Mace Rothenberg.
Some interesting pieces from this link
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3519950/
"Moreover, CD107a expression induced by the TriKE was significantly greater than the levels induced by rituximab. To evaluate whether this increased function was due to the surface expression levels of CD19, CD20 and CD22 on the primary ALL, CLL and AML leukemia targets, expression of these B-cell antigens was measured via FACS analysis (Figures 6B and 6C). Variations in surface expression of these receptors between patient samples were observed within each type of primary leukemia. The overall CD19, CD20 and CD22 expression profile of the primary leukemia targets suggests there may be an advantage to targeting two tumor-antigens rather than one."
"ALL and CLL tumors. Notably, the TriKE was significantly superior to rituximab in targeting of ALL and CLL. "
Rituxan has annual sales of 5 billion.
I think Cataldo might do a shareholder letter tomorrow or there will be an update on OXS-1550 on Tuesday I'm guessing.
https://clinicaltrials.gov/ct2/show/study/NCT03214666
Trial starts October 1st, right as new management comes in.
Should see some data from the TriKE platform before Thanksgiving
Why do you keep switching currency in the post, did you spend 18,232 dollars correct?
anyways 18,232 spent to get 529,844 shares, equals a price of $0.0344 per share. Assuming a 100-1 split you will have 5,298.44 shares at a cost of $3.44 per share
$3.44*5298= 18,225 if they round down however if they round up it will be worth $18,228.56
You will be fine.
Correct you will have 5300 shares at $3.44 each.
I'm sure I don't need to tell you this, but I would strongly recommend holding on to the majority of your shares until Oxis is acquired.
When they are acquired your total investment will be worth well over 100K because again OXS-3550 has the potential to cure certain types leukemia.
I don't say that lightly, the National Cancer Institute has said il-15 potentially holds the cure for curing cancer.
And also OXS-3550 was given the REACH award and grant from the National Institute of Health , and was stated most likely for commercialization.
Oxis most likely received this award from the NIH because OXS-3550 contains IL-15 .
OXS-3550 also contains CD 16 and 33.
So yeah, just to conclude and sorry for being redundant, but the real value of Oxis is in the TriKE platform, most specifically OXS-3550.
Best case scenario 20 to 25X
Sorry the reverse split (assume 100-1 reverse split) will happen and they will sell shares at assuming a price of $10 per share and they'll sell 50 million shares.
I will say this, you got in pretty cheap, so assuming a 100-1 split your price per share is $3.44 and even after they sell an additional 46 million shares. That'll mean there are 50 mil outstanding. So if the company is acquired for 500 million that'll be $10 per share. 1 billion $20 per share. 2-3 billion would be $40.00-$60.00 per share. You will do well with this investment.
The people who won't however are the ones who got in before the previous reverse split, they really got screwed by Tony.
It all depends on the success or failure of the pipeline in the clinical trials. Again if OXS-1550 or
OXS-3550 are approved the company is worth over 1 billion dollars. However if both of them fail, unless the TriKE platform works for solid tumors, which is highly unlikely especially if in this case it didn't work with liquid tumors. The company is worthless. So again in terms of how much the company is worth, we have to wait for the data from the clinical trials.
December of this year will be an important time, because by this point the clinical trial using the TriKE platform for both solid and liquid tumors will have begun. Early data (in vivo) for TriKE for liquid tumors looks very promising, and if all goes as planned, could go through the clinic much faster than OXS-1550.
I think the real value in this company is in OXS-3550 which as stated above, uses the TriKE platform for liquid tumors. This is why I believe Altor Bioscience Corp partnered with Oxis for this trial.
June of next year will also be an important time for the company, this is when the phase l/ll trial ends and we see final results from OXS-1550.
Worth case: company is almost worthless
Best Case: The company is worth 2-3 billion.
Assuming there is a 100-1 reverse split in order to uplist, your cost per share would still only be $1.60 a share so you will be fine.
Maybe that also(in regards to the anti-takeover), however in order for the TriKE platform for both solid and liquid tumors to enter the clinic, they will need to raise cash. (This is why the will need to sell additional shares.)
I don't know what company Pfizer bought for 30 billion, however I can GUARANTEE you that if they paid 30 billion for them. The company must already have drugs on the markets plus currently filing NDA for new drugs plus multiple drugs in phase 2/3 in the pipeline.
I'm sorry but the chance of Oxis selling for anywhere near 30 billion is nil. Sorry I'm hoping for the best too, but 30will never happen.
Here are my thoughts in regards to Oxis being acquired by Pfizer
1-2 billion assuming either OXS-1550 or OXS-3550 is approved for liquid tumors
2-3 billion assuming either OXS-1550 or OXS-3550 is approved for liquid tumors and the CNS drugs are approved.
Best case scenario and again won't actually happen, 10+ billion assuming TriKE platform shows efficacy for both liquid and solid tumors. (Essentially curing cancer) And the CNS drugs they acquire are approved.
For the reverse split, unless the stock price of OXIS gets above $0.5 in the near term (the only way this would happen is if data from OXS-1550 is stelar) there will be anywhere from a 1-50 to 1-300.
Side note, if the multiple myeloma drug ever enters the clinic and the data looks promising. Consider MCET because MCET is entitled to 3% of sale royalties from the multiple myeloma drug. However until/unless that happens, don't invest in MCET as of right now the company is worthless.
Just curious, what is your current cost per share for oxis, you don't have to tell me how many shares you have.
There are currently 400 million outstanding shares.
Assume they do a 100-1 reverse split in order to uplist. Now they will have 4 million shares outstanding however, now you'll only have a hundredth of what you had prior to the split. Example, I'll give you my current investment in Oxis. I currently have 130,000 shares at a price of $0.074 per share. After the split I'll now have 1,300 shares at a price of $7.4 per share. Assuming after the up list they sell an additional 56 million shares. They will now have 60 million outstanding (4 million from the reverse split plus 56 million from the ipo). As long as the stock price stays at or above $7.40 with a market cap of 444 million. I'm okay. Anything below that, I'm losing money.
So again my answer is I think there will be a total of 60 million shares outstanding after the reverse split.
The reason they won't have anywhere near 750 million after the split, is because then they remain a penny stock. (In order for them to not be a penny stock with 750 million shares outstanding, they'd need a price per share of $5.00 which would assume a 3.75 billion market cap.) Which until they at the very least have a phase three trial ongoing or NDA is highly unlikely.
So again my answer is I think there will be a total of 60 million shares outstanding after the reverse split.
Worst case scenario, 100 million, but remember this is after the reverse split.
Kite Pharma: 57 million source NASDAQ
Juno Therapeutics : 106 million outstanding source NASDAQ
Bluebird Bio: 41 million outstanding source NASDAQ
The minimum would be in line with what other (Blincycto) leukemia drugs have been acquired for. So about 1.2 billion, (assuming success in the clinic for OXS-1550 or OXS-3550).
Maximum. In the ABSOLUTE best case scenario over 10. HOWEVER this would be contingent upon success in the clinic for SOLID TUMORS using the TriKE platform. Listen to the interview in the link below. Dr. Jeffery Miller, says the holy grail not just for TriKE but for any platform is solid tumors. Solid tumors make up a little over 75% of cancer. And so that means should their be success in the clinic for solid tumors. That the TriKE platform could be used for multiple different types of cancers and also leukemia. DON'T COUNT ON THIS HAPPENING THOUGH THIS IS VERY UNLIKELY TO HAPPEN
https://player.fm/series/chi-podcasts/pegs-boston-2017-generation-of-bikes-and-trikes
In terms of what I think the company will be acquired for? I think what will happen is the same thing is what happened with the new ceos previous company Chase. Oxis will be acquired before any of its drug have finished their trials for 500 million. However, assuming continued success in the trials, That amount could easily exceed 2 billion upon achieving certain milestones. (I.E moving into phase 3 potentially a royalty off sales once the drug is approved)
Finally, I'm going to assume a 1 for 100 reverse split. I believe once they publicly announce data from the OXS-1550, oxis share price will reach 10 cents a share. At this price they will do a reverse split up list to the nasdaq and do an ipo at $10 a share. Averse a reverse split there will be 4 million shares outstanding, and by the time the company is acquired there will be 60 million. (Additional selling of shares needed to fund the continuing trials and to compensate management.)
Here's the good news, thank God Cataldo is gone, the new management will not allow 750 million outstanding shares. I am sure Dr. Kathleen has no interest in running a penny stock. And once she officially becomes ceo, she will up list the company right away.
Sorry didn't answer this earlier thought all there was was (I agree with you!)
I don't know if you were talking about me, however for what it's worth I been invested in this company for over a year. I've been following the board I just haven't said anything until now.
And I agree with what you and others on this board have been saying, I don't like Anthony Cataldo as their CEO. His lack of transparency in regards to Oxis has made it difficult for investors to understand how the company is doing and thus has negatively affected the stock price.
Just click on figures and data on the link below. I think you'll agree with me (and the data) in that the TriKE platform looks promising. I believe the clinical trial with Altor Bioscience will go well.
http://www.bloodjournal.org/content/128/22/4291/tab-figures-only
I think Oxis will be acquired in by '19 by a large pharmaceutical company (Pfizer) assuming data for OXS-1550 is promising and TRiKe clinical trials go as planned
Here are my reasons
OXS-1550 Phase two data will be available in June of '18
By the end of this year Oxis will have at least two additional drugs in the clinic (Not including the drugs acquired in their recent acquisition.)
OXS-3550 for liquid tumors. The TRiKE platform has shown promising in vivo data compared to
BiKEs . (The addition of Il-15 created NK cell proliferation resulting in 60-70% remission vs 30-
50% for BiKE)
OXS-4550 Again using the TRiKE platform In Vivo data isn't yet, however Dr. Miller assured me in
the email that they've made significant progress with it.
OXS-4235 There's a chance (albeit slim) that this Multiple Myeloma drugs enters the clinic this
year
Here's what I think will happen over the next few months,
Oxis will uplist to the nasdaq and will change the company name. In order to do this they will do
a reverse split, then fund operations through selling shares at a price of $10.00 per share.
However, unfortunately for us, I believe they won't announce that Mace Rothenberg is the CMO
and instead save that for after the reverse split when they uplist.
Initiate the two clinical trials. The one trial OXS-3550 is a partnership with Altor Bioscience
which is owned by Dr. Patrick Soon Shiong.
Towards the end of the year and more probably next year, Pfizer will license the TRiKE platform
from Oxis
Final thoughts
Why do I think a top oncologist like Mace Rotherberg is even bothering with a small biotech
company like Oxis? Because he sees the potential the TRiKE platform and for the CNS piepline.
This isn't the first time Mace has done this. According to the Wall Street Journal, in November of
2011 Dr. Rothenberg. Flew out to California to look at promising clinical data for the compound
PD-0332991. However Pfizer wasn't willing to fund the continuing clinical trials and so he raised
money from outside investors. PD-0332991 went on to become ibrance and was initially licensed
to Pfizer and then Pfizer later on acquired the company in its entirety. But this isn't it, prior to
this, Pfizer had licensed an alzheimers drug named Dimebon from this company for 225 million.
This explains why Oxis acquired Georgetown Translational Pharmaceuticals. So whats the name
of this company. Medivation, a company Pfizer acquired for 14 billion or $81.50 a share.
According to a press release from 05/05/2017 "Both our TriSpecific Killer Engager (TriKE) and
Bispecific Killer Engager (BiKE) platforms are applicable to solid tumors (80% of the
marketplace) and liquid tumors (20% of the market). In addition to our planned clinical
development program, our strategy will include potentially out-licensing the technology to
Pharma and other biotech companies for specific applications," said Oxis Chairman & Chief
Executive Officer Anthony Cataldo.
http://www.nasdaq.com/press-release/oxis-international-expands-its-stateoftheart-trike-
technology-portfolio-20170503-00696
And there's also this from Mase Rothernberg. Oxis' incoming CMO said: "The drugs in the Oxis
pipeline are at the forefront of targeted immunotherapeutics and represent the wave of the future.
The non-clinical and clinical data is impressive and validates this approach to cancer therapy.
Once approved, these agents will herald a major breakthrough in the field of immunotherapy and
offer patients hope against some of the most difficult diseases to treat."
Keep in mind this is the
guy who said "I think we have something special" his words not mine in regards to PD-0332991
according to the wall street journal. PD-0332991 went on to later become IBRANCE.